NOD2 sirna

NOD2 siRNA (Human)

Cat. Num. AAA8224622

• Gene Names: NOD2; CD; ACUG; BLAU; IBD1; NLRC2; NOD2B; CARD15; CLR16.3; PSORAS1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: NOD2; NOD2 siRNA (Human); CARD15; IBD1; Nucleotide-binding oligomerization domain-containing protein 2; Caspase recruitment domain-containing protein 15; Inflammatory bowel disease protein 1; NOD2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: NOD2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1013

• Applicable Applications for NOD2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human NOD2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for NOD2 sirna

siRNA to inhibit NOD2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 649572336
• NCBI GeneID: 64127
• NCBI Accession #: NP_001280486.1
• NCBI GenBank Nucleotide #: NM_001293557.1
• UniProt Accession #: Q9HC29; Q96RH5; Q96RH6; Q96RH8; E2JEQ6
• Molecular Weight: 22,403 Da
• NCBI Official Full Name: nucleotide-binding oligomerization domain-containing protein 2 isoform 2
• NCBI Official Synonym Full Names: nucleotide-binding oligomerization domain containing 2
• NCBI Official Symbol: NOD2
• NCBI Official Synonym Symbols: CD; ACUG; BLAU; IBD1; NLRC2; NOD2B; CARD15; CLR16.3; PSORAS1
• NCBI Protein Information: nucleotide-binding oligomerization domain-containing protein 2
• UniProt Protein Name: Nucleotide-binding oligomerization domain-containing protein 2
• Protein Family: Nucleotide-binding oligomerization domain-containing protein
• UniProt Gene Name: NOD2
• UniProt Synonym Gene Names: CARD15; IBD1
• UniProt Entry Name: NOD2_HUMAN

NCBI Description

This gene is a member of the Nod1/Apaf-1 family and encodes a protein with two caspase recruitment (CARD) domains and six leucine-rich repeats (LRRs). The protein is primarily expressed in the peripheral blood leukocytes. It plays a role in the immune response to intracellular bacterial lipopolysaccharides (LPS) by recognizing the muramyl dipeptide (MDP) derived from them and activating the NFKB protein. Mutations in this gene have been associated with Crohn disease and Blau syndrome. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jun 2014]

Uniprot Description

NOD2: Induces NF-kappa-B via RICK (CARDIAK, RIP2) and IKK- gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS). Defects in NOD2 are the cause of Blau syndrome (BS). BS is a rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash. Defects in NOD2 are a cause of susceptibility to inflammatory bowel disease type 1 (IBD1). IBD1 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Defects in NOD2 are the cause of sarcoidosis early-onset (EOS). EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early- onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement. 2 isoforms of the human protein are produced by alternative initiation.

Chromosomal Location of Human Ortholog: 16q21

Cellular Component: signalosome; cytoskeleton; cell surface; protein complex; cytoplasm; plasma membrane; cytosol; vesicle

Molecular Function: protein binding; peptidoglycan binding; enzyme binding; CARD domain binding; protein kinase binding; ATP binding; muramyl dipeptide binding

Biological Process: activation of MAPK activity; maintenance of gastrointestinal epithelium; positive regulation of dendritic cell antigen processing and presentation; stress-activated MAPK cascade; response to lipopolysaccharide; positive regulation of interleukin-1 beta secretion; toll-like receptor 3 signaling pathway; positive regulation of interleukin-10 production; activation of NF-kappaB transcription factor; negative regulation of interleukin-2 production; toll-like receptor 5 signaling pathway; positive regulation of gamma-delta T cell activation; positive regulation of phagocytosis; JNK cascade; detection of muramyl dipeptide; cytokine production during immune response; detection of biotic stimulus; toll-like receptor 4 signaling pathway; positive regulation of oxidoreductase activity; positive regulation of interleukin-17 production; negative regulation of interleukin-12 production; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of T-helper 2 type immune response; positive regulation of dendritic cell cytokine production; positive regulation of interleukin-6 production; positive regulation of tumor necrosis factor production; protein oligomerization; toll-like receptor 2 signaling pathway; negative regulation of interleukin-18 production; positive regulation of peptidyl-tyrosine phosphorylation; defense response to Gram-positive bacterium; innate immune response in mucosa; inhibition of NF-kappaB transcription factor; response to muramyl dipeptide; positive regulation of B cell activation; defense response to bacterium; positive regulation of transcription from RNA polymerase II promoter; toll-like receptor 9 signaling pathway; negative regulation of T cell mediated immunity; positive regulation of epithelial cell proliferation; positive regulation of nitric-oxide synthase biosynthetic process; detection of bacterium; positive regulation of interleukin-12 production; positive regulation of JNK cascade; defense response; positive regulation of stress-activated MAPK cascade; toll-like receptor 10 signaling pathway; response to exogenous dsRNA; negative regulation of interferon-gamma production; negative regulation of inflammatory response to antigenic stimulus; positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; response to nutrient; positive regulation of Notch signaling pathway; positive regulation of humoral immune response mediated by circulating immunoglobulin; MyD88-independent toll-like receptor signaling pathway; negative regulation of toll-like receptor 2 signaling pathway; positive regulation of phosphoinositide 3-kinase activity; negative regulation of tumor necrosis factor production; immunoglobulin production during immune response; MyD88-dependent toll-like receptor signaling pathway; positive regulation of interleukin-1 beta production; regulation of inflammatory response; toll-like receptor signaling pathway; innate immune response

Disease: Psoriatic Arthritis, Susceptibility To; Sarcoidosis, Early-onset; Inflammatory Bowel Disease 1; Blau Syndrome